Hsbc Holdings PLC Has $509,000 Stock Position in MannKind Corporation $MNKD

Posted by George Bondi on Aug 1st, 2026

Hsbc Holdings PLC boosted its stake in shares of MannKind Corporation (NASDAQ:MNKD – Free Report) by 198.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 212,038 shares of the biopharmaceutical company’s stock after acquiring an additional 140,970 shares during the quarter. Hsbc Holdings PLC’s holdings in MannKind were worth $509,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rubric Capital Management LP bought a new position in shares of MannKind in the third quarter worth about $61,297,000. Frazier Life Sciences Management L.P. bought a new stake in shares of MannKind during the fourth quarter valued at approximately $23,956,000. State Street Corp grew its stake in shares of MannKind by 36.2% during the fourth quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock valued at $82,914,000 after purchasing an additional 3,883,071 shares during the last quarter. UBS Group AG increased its holdings in shares of MannKind by 146.7% in the third quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock valued at $27,896,000 after purchasing an additional 3,088,820 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of MannKind by 316.2% in the third quarter. Wellington Management Group LLP now owns 3,467,721 shares of the biopharmaceutical company’s stock valued at $18,622,000 after purchasing an additional 2,634,533 shares in the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Price Performance

Shares of NASDAQ:MNKD opened at $3.91 on Friday. MannKind Corporation has a one year low of $2.23 and a one year high of $6.51. The company has a 50 day moving average of $3.90 and a 200-day moving average of $3.83. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -55.85 and a beta of 1.09.

MannKind (NASDAQ:MNKD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). MannKind had a negative return on equity of 11.21% and a negative net margin of 6.63%.The business had revenue of $90.17 million for the quarter, compared to the consensus estimate of $105.38 million. During the same period last year, the firm earned $0.04 earnings per share. The company’s quarterly revenue was up 15.1% on a year-over-year basis. Equities research analysts anticipate that MannKind Corporation will post -0.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on MNKD shares. Wall Street Zen upgraded shares of MannKind from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a research report on Wednesday, July 8th. Royal Bank Of Canada lifted their target price on MannKind from $3.50 to $4.75 and gave the company a “sector perform” rating in a research note on Thursday, May 7th. HC Wainwright restated a “buy” rating on shares of MannKind in a research report on Thursday, July 23rd. Finally, Zacks Research lowered MannKind from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.34.

View Our Latest Stock Report on MNKD

Insider Buying and Selling

In other MannKind news, Director Steven B. Binder sold 16,940 shares of MannKind stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $3.29, for a total transaction of $55,732.60. Following the completion of the sale, the director owned 808,008 shares of the company’s stock, valued at approximately $2,658,346.32. The trade was a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.60% of the company’s stock.

MannKind Profile

(Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).